A Phase 1, Single-arm, Single-center, Open-label, Prospective Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Latest Information Update: 07 Apr 2026
At a glance
- Drugs WSKIM 02 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors Westvac Biopharma
Most Recent Events
- 13 Mar 2026 New trial record